Total Payments
$102,544
2024 Payments
$29,436
Companies
40
Transactions
479
Medicare Patients
9,064
Medicare Billing
$1.4M
Payment Breakdown by Category
Other$52,618 (51.3%)
Research$25,924 (25.3%)
Food & Beverage$10,148 (9.9%)
Travel$6,923 (6.8%)
Consulting$6,840 (6.7%)
Education$91.78 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $52,618 | 31 | 51.3% |
| Unspecified | $25,924 | 7 | 25.3% |
| Food and Beverage | $10,148 | 397 | 9.9% |
| Travel and Lodging | $6,923 | 33 | 6.8% |
| Consulting Fee | $6,840 | 3 | 6.7% |
| Education | $91.78 | 8 | 0.1% |
Payments by Type
General
$76,620
472 transactions
Research
$25,924
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Pharma plc | $34,637 | 49 | $0 (2018) |
| Horizon Therapeutics plc | $25,894 | 38 | $0 (2023) |
| Eli Lilly and Company | $25,564 | 6 | $0 (2024) |
| GlaxoSmithKline, LLC. | $6,103 | 27 | $0 (2024) |
| Janssen Biotech, Inc. | $2,154 | 31 | $0 (2024) |
| Amgen Inc. | $1,907 | 65 | $0 (2024) |
| ABBVIE INC. | $1,832 | 55 | $0 (2024) |
| PFIZER INC. | $893.74 | 73 | $0 (2024) |
| UCB, Inc. | $509.05 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $447.98 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,436 | 166 | Eli Lilly and Company ($20,014) |
| 2023 | $2,527 | 32 | Janssen Biotech, Inc. ($1,742) |
| 2022 | $651.69 | 19 | Eli Lilly and Company ($234.00) |
| 2021 | $3,231 | 11 | Horizon Therapeutics plc ($1,608) |
| 2020 | $8,878 | 11 | Horizon Therapeutics plc ($4,863) |
| 2019 | $20,829 | 62 | Horizon Therapeutics plc ($19,387) |
| 2018 | $29,932 | 109 | Horizon Pharma plc ($28,478) |
| 2017 | $7,059 | 69 | Horizon Pharma plc ($6,160) |
All Payment Transactions
479 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $9.18 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $4.52 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/16/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | Fresenius Kabi USA, LLC | Tyenne (Biological) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Biosimilars | ||||||
| 12/11/2024 | Organon Llc | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: INFLIXIMAB | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $33.52 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Dermatology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $6.93 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $28.94 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $9.73 | General |
| Category: Bone Health | ||||||
| 11/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $4.57 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/13/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | Alvogen Inc | TERIPARATIDE (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: OSTEOPOROSIS | ||||||
| 11/06/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $29.76 | General |
| 11/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $41.17 | General |
| Category: Immunology | ||||||
| 11/04/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $30.04 | General |
| Category: Rheumatology | ||||||
| 10/31/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $25.01 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Dermatology | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | Eli Lilly and Company | TALTZ (Drug) | — | Cash or cash equivalent | $19,900.00 | Research |
| Study: EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) • Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $20,014 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $4,426 | 2 |
| A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Eli Lilly and Company | $1,123 | 2 |
| WEUKBRE6076: BELIMUMAB (BENLYSTA) PREGNANCY REGISTRY PROTOCOL | GlaxoSmithKline, LLC. | $360.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 2,114 | 5,923 | $407,158 | $170,577 |
| 2022 | 26 | 2,005 | 11,633 | $697,612 | $239,983 |
| 2021 | 31 | 2,423 | 22,081 | $1.7M | $461,820 |
| 2020 | 30 | 2,522 | 22,387 | $2.0M | $516,408 |
Total Patients
9,064
Total Services
62,024
Medicare Billing
$1.4M
Procedure Codes
116
All Medicare Procedures & Services
116 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 344 | 941 | $203,485 | $83,506 | 41.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 28 | 2,102 | $72,428 | $38,513 | 53.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 104 | 104 | $34,424 | $11,579 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 128 | 160 | $23,995 | $8,264 | 34.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 216 | 430 | $12,470 | $4,431 | 35.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 210 | 426 | $9,372 | $3,228 | 34.4% |
| 86480 | Tuberculosis test, gamma interferon | Office | 2023 | 47 | 50 | $6,250 | $3,037 | 48.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 216 | 352 | $3,520 | $2,941 | 83.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 16 | $4,695 | $2,245 | 47.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 19 | 21 | $7,140 | $2,159 | 30.2% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 218 | 425 | $6,375 | $2,149 | 33.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 18 | 18 | $2,916 | $1,598 | 54.8% |
| 85652 | Red blood cell sedimentation rate, to detect inflammation, automated | Office | 2023 | 218 | 425 | $3,400 | $1,121 | 33.0% |
| 82306 | Vitamin d-3 level | Office | 2023 | 36 | 37 | $2,775 | $1,073 | 38.7% |
| 86160 | Measurement of complement (immune system proteins), antigen, | Office | 2023 | 27 | 78 | $2,574 | $917.28 | 35.6% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 16 | 16 | $1,824 | $647.20 | 35.5% |
| 86225 | Measurement of dna antibody, native or double stranded | Office | 2023 | 27 | 39 | $1,482 | $525.33 | 35.4% |
| 86803 | Hepatitis c antibody measurement | Office | 2023 | 36 | 36 | $1,440 | $503.28 | 35.0% |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when perfor | Office | 2023 | 16 | 16 | $1,056 | $443.20 | 42.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 19 | 20 | $960.00 | $329.20 | 34.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 22 | $1,188 | $238.17 | 20.0% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 16 | 16 | $592.00 | $209.92 | 35.5% |
| 86200 | Measurement of antibody for rheumatoid arthritis assessment | Office | 2023 | 15 | 15 | $675.00 | $190.35 | 28.2% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 23 | 37 | $555.00 | $187.96 | 33.9% |
| 84156 | Total protein level, urine | Office | 2023 | 22 | 35 | $420.00 | $126.00 | 30.0% |
About Dr. Himabindu Reddy, MD
Dr. Himabindu Reddy, MD is a Rheumatology healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780658708.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Himabindu Reddy, MD has received a total of $102,544 in payments from pharmaceutical and medical device companies, with $29,436 received in 2024. These payments were reported across 479 transactions from 40 companies. The most common payment nature is "Honoraria" ($52,618).
As a Medicare-enrolled provider, Reddy has provided services to 9,064 Medicare beneficiaries, totaling 62,024 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 116 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Fort Worth, TX
- Active Since 02/15/2006
- Last Updated 11/01/2019
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1780658708
Products in Payments
- KRYSTEXXA (Drug) $34,637
- KRYSTEXXA (Biological) $26,201
- TALTZ (Drug) $19,984
- BENLYSTA (Biological) $5,949
- TREMFYA (Drug) $1,968
- RINVOQ (Biological) $819.99
- XELJANZ (Drug) $790.43
- Humira (Biological) $708.42
- Otezla (Drug) $573.00
- Cimzia (Drug) $434.36
- Enbrel (Biological) $399.27
- COSENTYX (Biological) $277.85
- EVENITY (Biological) $256.28
- TAVNEOS (Drug) $251.65
- KEVZARA (Biological) $229.12
- Prolia (Biological) $228.04
- ORENCIA (Biological) $217.23
- SAPHNELO (Biological) $164.44
- SIMPONI ARIA (Biological) $152.93
- LUPKYNIS (Drug) $118.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Fort Worth
Emily Isaacs, M.d, M.D
Rheumatology — Payments: $290,248
Rheumatology $290,248
Dr. Narayana Swamy, Md, MD
Rheumatology — Payments: $4,082
Rheumatology $4,082
Sampada Acharya, Md, MD
Rheumatology — Payments: $3,660
Rheumatology $3,660
Rahul Patel, Md, MD
Rheumatology — Payments: $2,255
Rheumatology $2,255
Rajni Kalagate, M.d, M.D
Rheumatology — Payments: $2,234
Rheumatology $2,234
Raza Jafry, M.d, M.D
Rheumatology — Payments: $1,919
Rheumatology $1,919